Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins
Background and aims Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. We investigated the potential usefulness of circulating apolipoproteins (Apo-A1 and Apo-A4) in HCC screening and diagnosis. Patients and methods We included 60 adult patients with h...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2019-01-01
|
| Series: | The Egyptian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.esim.eg.net/article.asp?issn=1110-7782;year=2019;volume=31;issue=4;spage=451;epage=457;aulast=El |
| _version_ | 1819204905402892288 |
|---|---|
| author | Hasan El Garem Gamal Esmat Rabab Salama Hanan Fouad Dina Sabry Yomna Mostafa Dalia Omran Heba Omar |
| author_facet | Hasan El Garem Gamal Esmat Rabab Salama Hanan Fouad Dina Sabry Yomna Mostafa Dalia Omran Heba Omar |
| author_sort | Hasan El Garem |
| collection | DOAJ |
| description | Background and aims Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. We investigated the potential usefulness of circulating apolipoproteins (Apo-A1 and Apo-A4) in HCC screening and diagnosis.
Patients and methods We included 60 adult patients with hepatitis C virus-related chronic liver disease including HCC, in addition to 20 healthy controls. Patients were stratified into three equal groups, with 20 patients each: chronic hepatitis C, posthepatitis C cirrhosis (liver cirrhosis), and HCC. All patients and controls underwent full clinical assessment, laboratory investigations, and evaluation of candidate apolipoproteins by enzyme-linked immunoassay.
Results Significantly higher Apo-A1 and Apo-A4 levels were detected in patients with HCC than in those with liver cirrhosis (P<0.001). Receiver operator characteristic curve showed that for HCC diagnosis, a cutoff of 78.6 mg/dl for Apo-A1 yielded 90% sensitivity and 100% specificity and a cutoff of 16.5 mg/dl for Apo-A4 yielded 85% sensitivity and 80% specificity. Furthermore, within HCC group, Apo-A1 was significantly higher in patients with small HCC (>2 cm) than those with large tumors (P=0.01). Lower Apo-A1 level correlated significantly with pylethrombosis (P=0.007).
Conclusion Apo-A1 and Apo-A4 are novel biomarkers for HCC screening and diagnosis, with a special discriminative ability for Apo-A1 for those with small tumors and those with pylethrombosis. |
| first_indexed | 2024-12-23T04:43:14Z |
| format | Article |
| id | doaj.art-ab3ea91286f14d8b8531c6e27eac961d |
| institution | Directory Open Access Journal |
| issn | 1110-7782 2090-9098 |
| language | English |
| last_indexed | 2024-12-23T04:43:14Z |
| publishDate | 2019-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Internal Medicine |
| spelling | doaj.art-ab3ea91286f14d8b8531c6e27eac961d2022-12-21T17:59:44ZengSpringerOpenThe Egyptian Journal of Internal Medicine1110-77822090-90982019-01-0131445145710.4103/ejim.ejim_26_19Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteinsHasan El GaremGamal EsmatRabab SalamaHanan FouadDina SabryYomna MostafaDalia OmranHeba OmarBackground and aims Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. We investigated the potential usefulness of circulating apolipoproteins (Apo-A1 and Apo-A4) in HCC screening and diagnosis. Patients and methods We included 60 adult patients with hepatitis C virus-related chronic liver disease including HCC, in addition to 20 healthy controls. Patients were stratified into three equal groups, with 20 patients each: chronic hepatitis C, posthepatitis C cirrhosis (liver cirrhosis), and HCC. All patients and controls underwent full clinical assessment, laboratory investigations, and evaluation of candidate apolipoproteins by enzyme-linked immunoassay. Results Significantly higher Apo-A1 and Apo-A4 levels were detected in patients with HCC than in those with liver cirrhosis (P<0.001). Receiver operator characteristic curve showed that for HCC diagnosis, a cutoff of 78.6 mg/dl for Apo-A1 yielded 90% sensitivity and 100% specificity and a cutoff of 16.5 mg/dl for Apo-A4 yielded 85% sensitivity and 80% specificity. Furthermore, within HCC group, Apo-A1 was significantly higher in patients with small HCC (>2 cm) than those with large tumors (P=0.01). Lower Apo-A1 level correlated significantly with pylethrombosis (P=0.007). Conclusion Apo-A1 and Apo-A4 are novel biomarkers for HCC screening and diagnosis, with a special discriminative ability for Apo-A1 for those with small tumors and those with pylethrombosis.http://www.esim.eg.net/article.asp?issn=1110-7782;year=2019;volume=31;issue=4;spage=451;epage=457;aulast=Elapolipoprotein-a1apolipoprotein-a4diagnosispylethrombosisscreeningsmall hepatocellular carcinoma |
| spellingShingle | Hasan El Garem Gamal Esmat Rabab Salama Hanan Fouad Dina Sabry Yomna Mostafa Dalia Omran Heba Omar Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins The Egyptian Journal of Internal Medicine apolipoprotein-a1 apolipoprotein-a4 diagnosis pylethrombosis screening small hepatocellular carcinoma |
| title | Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins |
| title_full | Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins |
| title_fullStr | Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins |
| title_full_unstemmed | Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins |
| title_short | Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins |
| title_sort | noninvasive prediction of hepatitis c associated hepatocellular carcinoma using circulating apolipoproteins |
| topic | apolipoprotein-a1 apolipoprotein-a4 diagnosis pylethrombosis screening small hepatocellular carcinoma |
| url | http://www.esim.eg.net/article.asp?issn=1110-7782;year=2019;volume=31;issue=4;spage=451;epage=457;aulast=El |
| work_keys_str_mv | AT hasanelgarem noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins AT gamalesmat noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins AT rababsalama noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins AT hananfouad noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins AT dinasabry noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins AT yomnamostafa noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins AT daliaomran noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins AT hebaomar noninvasivepredictionofhepatitiscassociatedhepatocellularcarcinomausingcirculatingapolipoproteins |